Aileron Therapeutics 将来の成長

Future 基準チェック /06

Aileron Therapeutics の収益は、年間 9.8% 減少すると予測されています。EPS は、年間増加すると予測されています3.4%。

主要情報

-9.8%

収益成長率

3.4%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aug 18

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Dec 30

業績と収益の成長予測

NasdaqCM:ALRN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-43	N/A	N/A	2
12/31/2025	N/A	-36	N/A	N/A	2
12/31/2024	N/A	-24	N/A	N/A	2
9/30/2024	N/A	-29	-28	-28	N/A
6/30/2024	N/A	-25	-26	-26	N/A
3/31/2024	N/A	-18	-20	-20	N/A
12/31/2023	N/A	-16	-20	-20	N/A
9/30/2023	N/A	-13	-14	-14	N/A
6/30/2023	N/A	-17	-19	-19	N/A
3/31/2023	N/A	-24	-22	-22	N/A
12/31/2022	N/A	-27	-25	-25	N/A
9/30/2022	N/A	-30	-27	-27	N/A
6/30/2022	N/A	-30	-27	-27	N/A
3/31/2022	N/A	-28	-25	-25	N/A
12/31/2021	N/A	-26	-24	-24	N/A
9/30/2021	N/A	-24	-22	-22	N/A
6/30/2021	N/A	-23	-20	-20	N/A
3/31/2021	N/A	-21	-21	-21	N/A
12/31/2020	N/A	-21	-20	-20	N/A
9/30/2020	N/A	-23	-22	-22	N/A
6/30/2020	N/A	-26	-24	-24	N/A
3/31/2020	N/A	-29	-25	-25	N/A
12/31/2019	N/A	-29	-27	-26	N/A
9/30/2019	N/A	-29	-29	-27	N/A
6/30/2019	N/A	-29	-31	-27	N/A
3/31/2019	N/A	-31	-33	-28	N/A
12/31/2018	N/A	-32	-32	-28	N/A
9/30/2018	N/A	-31	-30	-27	N/A
6/30/2018	N/A	-30	N/A	-25	N/A
3/31/2018	N/A	-26	N/A	-22	N/A
12/31/2017	N/A	-23	N/A	-21	N/A
9/30/2017	N/A	-20	N/A	-19	N/A
6/30/2017	N/A	-18	N/A	-18	N/A
3/31/2017	N/A	-19	N/A	-17	N/A
12/31/2016	N/A	-18	N/A	-15	N/A
9/30/2016	N/A	-17	N/A	-14	N/A
6/30/2016	N/A	-16	N/A	-12	N/A
3/31/2016	N/A	-14	N/A	-12	N/A
12/31/2015	N/A	-13	N/A	-12	N/A
9/30/2015	N/A	-13	N/A	-13	N/A
6/30/2015	N/A	-13	N/A	-12	N/A
3/31/2015	N/A	-15	N/A	-15	N/A
12/31/2014	N/A	-16	N/A	-17	N/A
12/31/2013	22	0	N/A	-14	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ALRN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ALRN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ALRN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ALRNの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ALRN来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ALRNの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Aileron Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 44% to US$13.00

Price target decreased to US$2.00

Price target decreased to US$2.00

Recent updates

New major risk - Financial position

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

New major risk - Share price stability

New minor risk - Share price stability

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 44% to US$13.00

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Aileron Therapeutics, Inc. announced delayed annual 10-K filing

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Aileron Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Share price stability

New minor risk - Shareholder dilution

Aileron Therapeutics, Inc. (NasdaqCM:ALRN) acquired Lung Therapeutics, Inc.

Aileron Therapeutics, Inc. announced that it expects to receive $16.4 million in funding from Nantahala Capital Management, LLC and other investors

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Insufficient new directors

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aileron Therapeutics Outlines Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Insufficient new directors

Insufficient new directors

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN 6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Appoints Susan L. Drexler as Interim Chief Financial Officer

Aileron Therapeutics, Inc. Appoints Manuel Aivado as Principal Financial Officer and Principal Accounting Officer

Aileron Therapeutics Announces First Patients Treated in Phase 1B Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics, Inc. Announces Resignation of Richard J. Wanstall as Chief Financial Officer, Effective from May 6, 2022

Price target decreased to US$2.00

Less than half of directors are independent

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$2.00

Less than half of directors are independent

Aileron Therapeutics: An Assessment On A Lottery Ticket

Aileron Therapeutics, Inc. Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics: Solving Chemotherapy's Toxicity

Aileron Therapeutics, Inc. Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $35.894081 million.

Aileron Therapeutics +31% on insider buying more shares

Aileron raises $40M via equity offering

Aileron Therapeutics EPS in-line

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.762 million.

Aileron Therapeutics, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Aileron Therapeutics, Inc.(NasdaqCM:ALRN) dropped from Russell Microcap Value Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘